A growing pool of evidence has indicated that overexpression of ILF2 is frequently observed in glioma, non-small cell lung cancer, esophageal squamous cell carcinoma, and childhood endodermal sinus tumors and is related to poor clinical outcomes [18,19,20,21]. This evidence concerns the gene ILF2 and glioma.